Cowen and Company’s ImmunityBio IBRX Stock Holding History

Cowen and Company’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-200,000	Closed	-$1.26M	–	656
2024 Q2	$1.26M	Buy	+200,000	New	+$1.32M	0.03%	142

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cowen and Company's IBRX Position: Q3 2024 in Review

Cowen and Company sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 200,000 shares — an estimated $1.26M sold.

Cowen and Company first reported a position in IBRX in Q2 2024 and held it in 1 quarter. The position peaked at $1.26M in Q2 2024. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

Cowen and Company reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
Cowen and Company sold 200,000 ImmunityBio shares in Q3 2024, an estimated $1.26M.
Cowen and Company first reported a position in ImmunityBio in Q2 2024 and held it in 1 quarter.
Cowen and Company's ImmunityBio position peaked at $1.26M in Q2 2024.
181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on Cowen and Company's 13F filing for Q3 2024, filed 12 Nov 2024.